Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsuniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]
Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.
Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.
ACR Convergence 2025 Recap: Late-Breaking Trials to Know
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial
1.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
2.
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
3.
Prostate cancer explained: From antigen tests to treatment options
4.
Review looks at potential treatment targets in the tumor microenvironment.
5.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
1.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
2.
The benefits of using magnesium sulfate during pregnancy
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
5.
Revolutionizing Cancer Care with Fulphila: A New Hope for Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
2.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
3.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
5.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge